文献速递肝胆胰外科

保留胰腺的远端胰腺切除术治疗胰导管腺癌的临床疗效

Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma.
PubMed 文献 · Surgery · 2024-12-12

该回顾性研究纳入2012至2022年同一机构98例因胰导管腺癌行远端胰腺切除术的患者,比较保留胰腺的远端胰腺切除术(16例)与传统远端胰腺切除术的手术结局、总生存和术后胰腺功能。结果显示保留胰腺组清扫淋巴结较少,但R0切除率、无复发生存和总生存相似,且糖尿病恶化比例较低、非酒精性脂肪性肝病新发比例更低。

要点

  • 保留胰腺的远端胰腺切除术并未影响R0切除率、无复发生存和总生存。
  • 该术式清扫淋巴结数量少于传统远端胰腺切除术(19枚 vs 31枚)。
  • 保留胰腺组术后新发非酒精性脂肪性肝病比例低于传统组(0% vs 22%)。

核心结论

  • 在能够实现R0切除的前提下,胰腺离断部位应更靠远端以保留术后胰腺功能。

研究设计与样本

  • 回顾性分析同一机构2012至2022年98例因胰导管腺癌行远端胰腺切除术的连续患者。
  • 保留胰腺的远端胰腺切除术定义为术后CT显示胰腺残端位于门静脉左缘的远端。
  • 比较保留胰腺的远端胰腺切除术(16例,16%)与传统远端胰腺切除术的手术结局、总生存和术后胰腺功能。

主要发现

  • 保留胰腺组清扫淋巴结数量少于传统组(19枚 vs 31枚,P < .01)。
  • 两组R0切除率相似(94% vs 93%,P = 1.00),无复发生存和总生存也相似。
  • 在局限于胰尾的胰导管腺癌患者中分析得到相似结果。
  • 保留胰腺组糖尿病恶化比例低于传统组(19% vs 39%,P = .16)。
  • 传统组22%患者新发非酒精性脂肪性肝病,保留胰腺组无新发(P = .04)。

临床怎么用

  • 对于胰导管腺癌拟行远端胰腺切除术者,在保证R0切除的前提下可考虑将胰腺离断部位更靠远端以保留胰腺功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term survival rate of patients with pancreatic ductal adenocarcinoma has improved alongside the development of multidisciplinary treatment, and there is now demand for less invasive surgery that maintains postoperative pancreatic function. We evaluated the efficacy of pancreas-preserving distal pancreatectomy in terms of oncologic parameters and postoperative pancreatic function. METHODS: The data of 98 consecutive patients who underwent distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma between 2012 and 2022 in our institution were retrospectively analyzed. The surgical outcomes, overall survival, and postoperative pancreatic function were compared between pancreas-preserving distal pancreatectomy, in which the pancreatic stump was distal to the left margin of the portal vein on postoperative computed tomography, and conventional distal pancreatectomy. RESULTS: Sixteen patients (16%) underwent pancreas-preserving distal pancreatectomy. Fewer lymph nodes were dissected in the pancreas-preserving distal pancreatectomy group than the conventional distal pancreatectomy group (19 vs 31, respectively; P < .01); however, the R0 resection rate (94% vs 93%, respectively; P = 1.00), recurrence-free survival, and overall survival were similar. Similar results were obtained in an analysis limited to patients with pancreatic ductal adenocarcinoma in the pancreatic tail. Patients who underwent pancreas-preserving distal pancreatectomy were less likely to develop worsening of their diabetes than those who underwent conventional distal pancreatectomy (19% vs 39%, respectively; P = .16). Nonalcoholic fatty liver disease newly developed in 22% of the patients who underwent conventional distal pancreatectomy but in none of those who underwent pancreas-preserving distal pancreatectomy (P = .04). CONCLUSION: The pancreatic transection site should be distally located to preserve postoperative pancreatic function when R0 resection can be achieved.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Ikenaga N, Nakata K, Abe T, et al. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Surgery. 2024. PMID: 39667108. doi:10.1016/j.surg.2024.108958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。